Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Hydromorphone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for This medicine has been prescribed for you for the relief of severe pain. It contains hydromorphone, which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking this medicine suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.
e Palladone injection Do not use Palladone injection if you:
Warnings and precautions Talk to your doctor or pharmacist before using Palladone injection if you:
–
You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction"). You are a smoker. You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses.
If you notice any of the following signs whilst taking Palladone injection, it could be a sign that you have become dependent or addicted: –
You need to take the medicine for longer than advised by your doctor. You need to take more than the recommended dose. You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain. You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'. You have made repeated, unsuccessful attempts to quit or control the use of the medicine. When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects').
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking { Palladone injection}). Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your doctor will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. You may experience hormonal changes whilst using this medicine. Your doctor may want to monitor these changes. If this information applies to you or formerly applied to you, please speak to your doctor. Palladone injection is not recommended for children under 12 years of age. The major risk of opioid excess is difficulty in breathing (respiratory depression). Please tell your doctor if you experience small bowel problems (paralytic ileus) during treatment with this medicine. He or she will take appropriate measures. If you are going to have an operation, please tell the doctor at the hospital that you are using this medicine as they may need to adjust the amount of injection you are given.
The use of this medicine may produce positive results in doping controls. Other medicines and Palladone injection Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. When taken with some other medicines or alcohol, the side effects of Palladone injection (such as drowsiness, breathing problems, constipation, dry mouth, difficulty in passing urine) or the other medicine may be altered. Tell your doctor if you:
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Pregnancy Do not use Palladone injection if you are pregnant or think you might be pregnant unless you have discussed this with your doctor and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Palladone injection during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated, such as high-pitched cry, jitteriness, fits, poor feeding and diarrhoea. If you use this medicine during labour, uterine contractility may be impaired. In addition slow and shallow breathing (respiratory depression) may occur in the newborn infant. Breast-feeding Do not use Palladone injection while you are breastfeeding as hydromorphone passes into breast milk and will affect your baby. Driving and using machines This medicine may make you drowsy and thus impair your ability to drive and use machines. This applies particularly:
Palladone injection Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
A doctor or nurse will usually prepare and administer the injection for you. Your doctor will decide how much Palladone injection you require based on:
If you get long term treatment, your doctor should verify regularly whether you still need this medicine. Do not stop the treatment without talking to your doctor (see "If you stop using Palladone injection"). If you use more Palladone injection than you should Call your doctor, hospital or an ambulance straight away as the patient may need emergency treatment in hospital. In severe cases an overdose may lead to unconsciousness, a brain disorder (known as toxic leukoencephalopathy), pneumonia caused by inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever) or even death. The following symptoms may occur after an overdose:
How do I know if I am addicted? If you notice any of the following signs whilst using Palladone injection it could be a sign that you have become addicted.
Rare side effects (may affect up to 1 in 1,000 people)
with unknown frequency (frequency cannot be estimated from the available data)
Palladone injection Keep this medicine out of the sight and reach of children. Keep the ampoules in the outer carton in order to protect from light. Do not use this medicine after the expiry date which is stated on the carton and the ampoule label after "EXP". The expiry date refers to the last day of that month. From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless opening/ dilution has taken place in controlled and validated aseptic conditions. The medicine is to be visually inspected prior to use. Only clear solutions free from particles should be used. Do not throw away any medicines via wastewater or household waste. Ask you pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Palladone injection contains: Palladone 2 mg/ml injection:
Information for Health Professionals Palladone® 2 mg/ml and 10 mg/ml solution for injection or infusion Hydromorphone hydrochloride This leaflet provides technical information for the healthcare professional about Palladone 2 mg/ml and 10 mg/ml, solutions for injection or infusion. Posology and method of administration Method of administration Intravenous injection or infusion Subcutaneous injection or infusion The medicinal product is to be visually inspected prior to use. Only clear solutions free from particles should be used. After opening, this medicinal product should be used immediately. Posology The dosing of Palladone injection has to be adjusted to the patients' severity of pain and to their individual response. The dose should be titrated until optimum analgesic effect is achieved. While the dose to be administered should be sufficient to achieve appropriate analgesia, the aim should also be to keep the dose as small as possible in the individual case. Palladone injection should not be administered for longer than absolutely necessary. If long-term treatment is required careful and regular monitoring should control whether and to what degree further treatment is necessary. When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. Age Bolus Adults and adolescents (>12 years) subcutaneous (s.c.) use 1-2 mg s.c. every 3-4 hours intravenous (i.v.) use PCA (s.c. and i.v.) Paediatric population (<12 years)
Infusion 0.15-0.45 mg/h 0.004 mg/kg bodyweight/h 0.15-0.45 mg/h 0.004 mg/kg bodyweight/h
1-1.5 mg i.v. every 3-4 hours to be injected slowly over at least 2-3 minutes 0.2 mg bolus, stop interval 5-10 min. Not recommended
Paediatric population Palladone injection is not recommended for use in children under 12 years of age as the safety and efficacy has not yet been established. No data are available. Elderly patients Elderly patients (as a rule over 75 years) may require a lower dosage than other adults to achieve adequate analgesia.
Patients with hepatic and/or renal impairment These patients may require lower doses than other patient groups to achieve adequate analgesia. They should be carefully titrated to clinical effect. Cessation of therapy When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. Special precautions for disposal and other handling Chemical and physical in-use stability has been demonstrated for 7 days at 4°C, 25°C and 37°C except for diluted solutions in polycarbonate syringes which should not be stored beyond 24 hours. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8 C, unless dilution has taken place in controlled and validated aseptic conditions. No evidence of incompatibility was observed between Palladone injection and representative brands of injectable forms of the following drugs, when stored in high and low dose combinations in polypropylene syringes over a 24 hour period at ambient temperature (25°C). Hyoscine butylbromide Hyoscine hydrobromide Dexamethasone sodium phosphate Haloperidol Midazolam hydrochloride Metoclopramide hydrochloride Levomepromazine hydrochloride Glycopyrronium bromide Ketamine hydrochloride No evidence of incompatibility was observed between Palladone injection, undiluted or diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion, glucose 50 mg/ml (5%) solution for infusion or water for injections, and representative brands of polypropylene syringes, polyethylene and PVC tubing and PVC or EVA infusion bags. Incompatibilities were observed with diluted solutions of 50 mg/ml when stored in polycarbonate syringes beyond 24 hours at 25°C. Whereas no evidence of incompatibility was found when the same preparations were stored at 4°C up to 7 days. The ampoules should be stored in the outer carton in order to protect from light. Inappropriate handling of the undiluted solution after opening of the original ampoule, or of the diluted solutions may compromise the sterility of the product. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. This leaflet was last revised in November 2025. ® Palladone and the NAPP logo are Registered Trade Marks. © 2012-2024 Napp Pharmaceuticals Limited
Palladone 2 mg/ml solution for injection or infusion comes as injection containing 2mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Palladone 2 mg/ml solution for injection or infusion is hydromorphone hydrochloride.
This leaflet reproduces the patient information leaflet approved for Palladone 2 mg/ml solution for injection or infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
For the relief of severe pain in cancer.
Palladone injection is indicated in adults and adolescents aged >12 years.
Method of administration
Intravenous injection or infusion
Subcutaneous injection or infusion
The medicinal product is to be visually inspected prior to use. Only clear solutions free from particles should be used.
After opening, this medicinal product should be used immediately (please refer to section 6.3).
For instructions on dilution of the medicinal product before administration, see section 6.6.
Posology
The dosing of Palladone injection has to be adjusted to the patients' severity of pain and to their individual response. The dose should be titrated until optimum analgesic effect is achieved.
While the dose to be administered should be sufficient to achieve appropriate analgesia, the aim should also be to keep the dose as small as possible in the individual case.
Duration of treatment:
Palladone injection should not be administered longer than absolutely necessary.
Treatment goals and discontinuation:
Before initiating treatment with Palladone injection, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed in order to minimise the risk of addiction and drug withdrawal syndrome. When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
Palladone 10 mg/ml injection is not suitable for initial opioid therapy. This higher strength may only be used as individual doses in patients who have no longer sufficiently responded to lower doses of hydromorphone preparations (Palladone 2 mg) or comparably strong analgesics within the scope of chronic pain therapy. The reservoir of a pain pump can also be filled with individual doses of 10 mg/ml as the dose control is secured by the pump calibration.
Age
Bolus
Infusion
Adults and adolescents (> 12 years)
subcutaneous (s.c.) use
1-2 mg s.c. every 3-4 hours
0.15-0.45 mg/h 0.004 mg/kg bodyweight/h
intravenous (i.v.) use
1-1.5 mg i.v. every 3-4 hours to be injected slowly over at least 2-3 minutes
0.15-0.45 mg/h 0.004 mg/kg bodyweight/h
PCA (s.c. and i.v.)
0.2 mg bolus, stop interval 5-10 min.
Paediatric population (< 12 years)
Not recommended
Transferring patients between oral and parenteral hydromorphone:
Switching patients from parenteral hydromorphone to oral hydromorphone should be guided by the sensitivity of the individual patient. The oral starting dose should not be overestimated (for oral bioavailability see section 5.2).
Paediatric population:
Palladone injection is not recommended for use in children under 12 years of age as the safety and efficacy has not yet been established. No data are available.
Elderly patients
Elderly patients (as a rule over 75 years) may require a lower dosage than other adults to achieve adequate analgesia.
Patients with hepatic and/or renal impairment
These patients may require lower doses than other patient groups to achieve adequate analgesia. They should be carefully titrated to clinical effect (see Section 5.2).
Hydromorphone is contra-indicated in patients with:
• Known hypersensitivity to hydromorphone or to any of the excipients listed in section 6.1.
• Severe respiratory depression with hypoxia and/or hypercapnia
• Severe chronic obstructive pulmonary disease
• Severe bronchial asthma
• Cor pulmonale,
• Coma
• Acute abdomen
• Paralytic ileus
• Concurrent administration of mono-amine oxidase inhibitors or within two weeks of discontinuation of their use.
Hydromorphone should be used with caution in the debilitated elderly and in patients with:
• Severely impaired respiratory function
• Sleep apnoea
• CNS depressants co-administration (see below and section 4.5)
• Head injury, intracranial lesions or increased intracranial pressure, reduced level of consciousness of uncertain origin
• Hypotension with hypovolaemia
• Pancreatitis
• Hypothyroidism
• Toxic psychosis
• Prostatic hypertrophy
• Adrenocortical insufficiency (e.g., Addison's disease)
• Severely impaired renal function
• Severely impaired hepatic function
• Convulsive disorders
• Alcoholism
• Delirium tremens
• Biliary tract diseases, biliary or ureteric colic
• Obstructive or inflammatory bowel disorders
• Reduced respiratory reserve
• Constipation
In all these patients, reduced dosage may be advisable.
Sleep-related breathing disorders
The major risk of opioid excess is respiratory depression.
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent manner (see section 4.8). Opioids may also cause worsening of pre-existing sleep apnoea (see section 4.8). In patients who present with CSA, consider decreasing the total opioid dosage.
Risk from concomitant use of sedative medicines such as benzodiazepines (and other CNS depressants)
Concomitant use of Palladone injection and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Palladone injection concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Tolerance and Opioid Use Disorder (abuse and dependence)
Tolerance, physical and/or psychological dependence may develop upon repeated administration of opioids such as hydromorphone.
Repeated use of Palladone injection can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Palladone injection may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with Palladone injection and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Drug dependence, tolerance and potential for abuse
For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g. major depression).
Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.
A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse or addiction.
The clinical need for analgesic treatment should be reviewed regularly.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with hydromorphone.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Palladone injection should not be used where the occurrence of paralytic ileus is possible. Should paralytic ileus be suspected or occur during use, hydromorphone treatment must be discontinued immediately.
Palladone injection should be used with caution pre- or intraoperatively and within the first 24 hours postoperatively.
Patients about to undergo additional pain-relieving procedures (e.g. surgery, plexus blockade) should not receive hydromorphone for 4 hours prior to the intervention. If further treatment with Palladone injection is indicated, the dosage should be adjusted to the post-operative requirement.
Opioids, such as hydromorphone, may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.
It should be emphasised that patients, once adjusted (titrated) to an effective dose of a specific opioid, should not be changed to other opioid analgesics without clinical assessment and careful retitration as necessary. Otherwise a continuous analgesic action is not ensured.
This medicinal product contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially “sodium-free”.
Central nervous system (CNS):
The concomitant use of opioids with sedative medicines such as benzodiazepines or other drugs that depress the CNS increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Drugs which depress the CNS include, but are not limited to: other opioids, anxiolytics, hypnotics and sedatives (including benzodiazepines), anaesthetics (e.g. barbiturates), antiemetics, antidepressants, antipsychotics (e.g. phenothiazines), antihistamines and alcohol.
Alcohol may also enhance the pharmacodynamic effects of hydromorphone; concomitant use should be avoided.
The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.
Medicinal products with an anticholinergic effect (e.g. psychotropics, antiemetics, antihistamines or antiparkinsonian medicinal products) may enhance the anticholinergic undesirable effects of opioids (e.g. constipation, dry mouth or urinary retention).
Concurrent administration of hydromorphone and mono-amine oxidase inhibitors or within two weeks of discontinuation of their use is contraindicated (see section 4.3).
No interaction studies have been performed.
Pregnancy
There are no well-controlled studies of hydromorphone in pregnant women.
Hydromorphone should not be used in pregnancy unless clearly necessary.
Palladone injection is not recommended during pregnancy and labour due to impaired uterine contractility. Regular use in pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in pregnant women, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breast-feeding
Administration to nursing women is not recommended as hydromorphone is excreted into breast milk in low amounts and may cause respiratory depression in the infant.
Fertility
Non clinical toxicology studies in rats have not shown any effects on male or female fertility or sperm parameters.
Hydromorphone may impair the ability to drive and use machines. This is particularly likely at the initiation of treatment with hydromorphone, after dose increase or product rotation and if hydromorphone is combined with alcohol or other CNS depressant substances. Patients stabilised on a specific dosage will not necessarily be restricted. Patients should therefore consult with their physician whether driving or the use of machinery is permitted.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
o The medicine is likely to affect your ability to drive.
o Do not drive until you know how the medicine affects you.
o It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence'). This defence applies when:
▪ The medicine has been prescribed to treat a medical or dental problem; and
▪ You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
o Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).”
Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law
The following frequency categories form the basis for classification of the undesirable effects:
Term
Frequency
Very common
≥ 1/10
Common
≥ 1/100 to < 1/10
Uncommon
≥ 1/1,000 to < 1/100
Rare
≥ 1/10,000 to < 1/1,000
Very rare
< 1/10,000
Not known
Frequency cannot be estimated from the available data
Immune system disorders:
Not known:
hypersensitivity (including oropharyngeal swelling), anaphylactic reactions
Metabolism and nutrition disorders
Common:
decreased appetite
Psychiatric disorders:
Common:
anxiety, confusional state, insomnia
Uncommon:
agitation, depression, euphoric mood, hallucinations, nightmares
Not known:
drug dependence (see section 4.4), dysphoria
Nervous system disorders:
Very common:
dizziness, somnolence
Common:
headache
Uncommon:
tremor, myoclonus, paraesthesia
Rare:
sedation, lethargy
Not known:
convulsions, dyskinesia, hyperalgesia (see section 4.4), central sleep apnoea syndrome
Eye disorders:
Uncommon:
visual impairment
Not known:
miosis
Cardiac disorders:
Rare:
bradycardia, palpitations, tachycardia
Vascular disorders:
Uncommon:
hypotension
Not known:
flushing
Respiratory, thoracic and mediastinal disorders:
Uncommon:
dyspnoea
Rare:
respiratory depression, bronchospasm
Gastrointestinal disorders:
Very common:
constipation, nausea
Common:
abdominal pain, dry mouth, vomiting
Uncommon:
dyspepsia, diarrhoea, dysgeusia
Not known:
paralytic ileus
Hepato-biliary disorders:
Uncommon:
hepatic enzymes increased
Rare:
elevation of pancreatic enzymes
Skin and subcutaneous tissue disorders:
Common:
pruritus, hyperhidrosis
Uncommon:
rash
Not known:
urticaria
Renal and urinary disorders:
Common:
urinary urgency
Uncommon:
urinary retention
Reproduction system and breast disorders:
Uncommon:
decreased libido, erectile dysfunction
General disorders and administration site conditions:
Common:
asthenia, injection site reactions
Uncommon:
drug withdrawal syndrome, fatigue, malaise, peripheral oedema
Very rare:
injection site induration (particularly after repeated s.c. administration)
Not known:
drug tolerance, drug withdrawal syndrome neonatal
Paediatric population:
For infants born to mothers receiving hydromorphone see section 4.6.
Description of selected adverse reactions
Drug dependence
Repeated use of Palladone injection can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Signs of hydromorphone intoxication and overdose include miosis, bradycardia, respiratory depression, hypotension, somnolence progressing to stupor and coma, and pneumonia aspiration. Circulatory failure and deepening coma may occur in more severe cases and may lead to a fatal outcome. Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Toxic leukoencephalopathy has been observed with hydromorphone overdose.
In unconscious patients with respiratory arrest intubation and assisted respiration may be required. An opioid antagonist (e.g. naloxone 0.4 mg) should be administered intravenously. Individual administration of the antagonist should be repeated at 2 to 3-minute intervals as necessary.
Close monitoring (at least for 24 hours) is required, since the effect of the opioid antagonist is shorter than that of hydromorphone, so that repeated occurrence of the signs of overdose like respiratory insufficiency are to be expected.
Ask anything about Palladone 2 mg/ml solution for injection or infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.